Maalot

Maalot is a pre-clinical stage biotechnology company focused on developing transformative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The company’s core strategy involves targeting TDP-43, an RNA-binding protein that forms toxic aggregates in the brains of patients with these conditions. By utilizing a proprietary platform to identify small molecules that restore healthy TDP-43 function or prevent its aggregation, Maalot seeks to address the underlying cause of neuronal death. Headquartered in Israel, the company is led by experienced pharmaceutical executives and supported by a syndicate of top-tier life science venture capital firms. The company's research is grounded in scientific discoveries from the Weizmann Institute of Science regarding RNA metabolism and protein homeostasis.